These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21488995)

  • 1. Biomarkers of therapy responsiveness in asthma: pitfalls and promises.
    Vijverberg SJ; Koenderman L; Koster ES; van der Ent CK; Raaijmakers JA; Maitland-van der Zee AH
    Clin Exp Allergy; 2011 May; 41(5):615-29. PubMed ID: 21488995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exhaled nitric oxide in the diagnosis and management of childhood asthma.
    Kercsmar C
    Ther Adv Respir Dis; 2010 Apr; 4(2):71-82. PubMed ID: 20215487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fluticasone on markers of inflammation and quality of life in steroid-naive patients with mild asthma.
    Ehrs PO; Sundblad BM; Larsson K
    Clin Respir J; 2010 Jan; 4(1):51-8. PubMed ID: 20298418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting short term response to anti-inflammatory therapy in young children with asthma.
    Zielen S; Christmann M; Kloska M; Dogan-Yildiz G; Lieb A; Rosewich M; Schubert R; Rose MA; Schulze J
    Curr Med Res Opin; 2010 Feb; 26(2):483-92. PubMed ID: 20001651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targets for new therapy for corticosteroid refractory asthma.
    Ito K; Mercado N
    Expert Opin Ther Targets; 2009 Sep; 13(9):1053-67. PubMed ID: 19659447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asthma control test (ACT): comparison with clinical, functional, and biological markers of asthma control.
    Melosini L; Dente FL; Bacci E; Bartoli ML; Cianchetti S; Costa F; Di Franco A; Malagrinò L; Novelli F; Vagaggini B; Paggiaro P
    J Asthma; 2012 Apr; 49(3):317-23. PubMed ID: 22401649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of response to asthma controller therapy: clinical implications.
    Langmack EL; Martin RJ
    Curr Opin Pulm Med; 2010 Jan; 16(1):13-8. PubMed ID: 19875959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomolecular markers in assessment and treatment of asthma.
    Fatemi F; Sadroddiny E; Gheibi A; Mohammadi Farsani T; Kardar GA
    Respirology; 2014 May; 19(4):514-23. PubMed ID: 24698542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive evaluation of airway inflammation in asthmatic patients who smoke: implications for application in clinical practice.
    Bessa V; Tseliou E; Bakakos P; Loukides S
    Ann Allergy Asthma Immunol; 2008 Sep; 101(3):226-32; quiz 232-4, 278. PubMed ID: 18814444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation between inflammation and symptoms in asthma.
    Tillie-Leblond I; Montani D; Crestani B; de Blic J; Humbert M; Tunon-de-Lara M; Magnan A; Roche N; Ostinelli J; Chanez P
    Allergy; 2009 Mar; 64(3):354-67. PubMed ID: 19210358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of exhaled nitric oxide in the diagnosis and management of asthma.
    Majid H; Kao C
    Curr Opin Pulm Med; 2010 Jan; 16(1):42-7. PubMed ID: 19797954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exhaled nitric oxide for monitoring childhood asthma inflammation compared to sputum analysis, serum interleukins and pulmonary function.
    Paro-Heitor ML; Bussamra MH; Saraiva-Romanholo BM; Martins MA; Okay TS; Rodrigues JC
    Pediatr Pulmonol; 2008 Feb; 43(2):134-41. PubMed ID: 18085692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers of inflammation in asthma: a clinical perspective.
    Taylor DR
    Semin Respir Crit Care Med; 2012 Dec; 33(6):620-9. PubMed ID: 23047312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitric oxide as a clinical guide for asthma management.
    Taylor DR
    J Allergy Clin Immunol; 2006 Feb; 117(2):259-62. PubMed ID: 16461124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial).
    Bjermer L; Bisgaard H; Bousquet J; Fabbri LM; Greening A; Haahtela T; Holgate ST; Picado C; Leff JA
    Respir Med; 2000 Jun; 94(6):612-21. PubMed ID: 10921768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods used in clinical development of novel anti-asthma therapies.
    Diamant Z; Boot D; Kamerling I; Bjermer L
    Respir Med; 2008 Mar; 102(3):332-8. PubMed ID: 18061420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current and future role of biomarkers in type 2 cytokine-mediated asthma management.
    Pavord ID; Afzalnia S; Menzies-Gow A; Heaney LG
    Clin Exp Allergy; 2017 Feb; 47(2):148-160. PubMed ID: 28134501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of FeNO measurement in asthma management: the motion for Yes, it's NO--or, the wrong end of the Stick!
    Bush A; Eber E
    Paediatr Respir Rev; 2008 Jun; 9(2):127-31. PubMed ID: 18513673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-dependent effects of inhaled corticosteroids on lung function, bronchial hyperresponsiveness, and airway inflammation in asthma.
    Mehta V; Stokes JR; Berro A; Romero FA; Casale TB
    Ann Allergy Asthma Immunol; 2009 Jul; 103(1):31-7. PubMed ID: 19663124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical utility of biomarkers in asthma and COPD.
    Snell N; Newbold P
    Curr Opin Pharmacol; 2008 Jun; 8(3):222-35. PubMed ID: 18468485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.